Literature DB >> 2161820

Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.

F Higashitani1, A Hyodo, N Ishida, M Inoue, S Mitsuhashi.   

Abstract

The in-vitro synergistic activity of tazobactam, a new beta-lactamase inhibitor, combined with piperacillin was tested against various beta-lactamase-producing strains. The beta-lactamase inhibitory activity of tazobactam against various known types of beta-lactamase was also tested in comparison with clavulanic acid or sulbactam. Tazobactam caused a remarkable reduction of the piperacillin MICs for penicillinase- and oxyiminocephalosporinase-producing strains and also showed a moderate synergistic effect against cephalosporinase-producing strains. The bactericidal activity of piperacillin was enhanced in combination with tazobactam. Tazobactam inhibited the penicillinases, and the oxyiminocephalosporinase produced by Proteus vulgaris, at low concentration. In these cases its activity was comparable with that of clavulanic acid and stronger than that of sulbactam. Tazobactam demonstrated a better inhibitory capability than sulbactam against the cephalosporinases tested. Tazobactam was able to inactivate intracellular beta-lactamase in Prot. vulgaris and Morganella morganii, confirming its ability to penetrate the cell membrane of these species.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161820     DOI: 10.1093/jac/25.4.567

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.

Authors:  S Gatermann; R Marre
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

2.  In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.

Authors:  K Nishida; C Kunugita; T Uji; F Higashitani; A Hyodo; N Unemi; S N Maiti; O A Phillips; P Spevak; K P Atchison; S M Salama; H Atwal; R G Micetich
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Structure-function studies of Ser-289 in the class C beta-lactamase from Enterobacter cloacae P99.

Authors:  S Trépanier; J R Knox; N Clairoux; F Sanschagrin; R C Levesque; A Huletsky
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

4.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

5.  Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.

Authors:  P Van der Auwera; V Duchateau; C Lambert; M Husson; M Kinzig; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 6.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

7.  Energetic Materials Based on N-substituted 4(5)-nitro-1,2,3-triazoles.

Authors:  Gennady T Sukhanov; Yulia V Filippova; Yuri V Gatilov; Anna G Sukhanova; Irina A Krupnova; Konstantin K Bosov; Ekaterina V Pivovarova; Vyacheslav I Krasnov
Journal:  Materials (Basel)       Date:  2022-01-31       Impact factor: 3.623

8.  In Vitro Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria.

Authors:  Shunian Xiao; Chuyue Zhuo; Chao Zhuo
Journal:  Comput Math Methods Med       Date:  2021-11-25       Impact factor: 2.238

9.  Piperacillin/Tazobactam (ZOSYN).

Authors:  S M Culver; M G Martens
Journal:  Infect Dis Obstet Gynecol       Date:  1996
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.